Background: Survivin is an inhibitor of apoptosis that may be a novel diagnostic and prognostic marker
of cancer. Our study is to investigate the diagnostic and prognostic value of
survivin for pleural effusions. Methods: Sixty-five pleural effusion
patients were enrolled prospectively. Pleural effusion samples were examined for survivin level by ELISA. Pleural
effusions were divided into three groups:
Group I, malignant pleural effusion (MPE) (n = 36); Group II, tuberculous pleurisy
(TPE) (n = 18); and Group III, transudative pleural effusion (n = 11). The
accuracy of diagnosis and the correlation between survivin level and survival
in malignant pleural effusions (MPE) were analyzed. Results: Survivin level was 320.50 ± 228.24 pg/ml in MPE, 328.35 ± 146.79 pg/ml in TPE and 318.87 ± 208.39 pg/ml in
transudative pleural effusion respectively. ROC curves for MPE versus TPE were
analyzed, area under the ROC curve was 0.419, and for the cutoff value
of 254.85 pg/ml sensitivity was 44.4% and specificity 55.6%.
Survivin had no discriminative power in differentiating
exudative effusions of MPE from non-MPE (p = 0.648). There was no correlation
between survivin level and age, sex. However, statistically significant
difference was found between primary lung carcinoma (238.66 ± 48.19 pg/ml) and
extra-pulmonary metastatic carcinomas (435.09 ± 320.62 pg/ml) according to
survivin level (p = 0.033). Survivin levels can distinguish patients who had poor prognosis (median survival 96 days)
and those who had good prognosis (median survival 206 days) in MPE. Conclusio
References
[1]
Marel, M., Stastny, B., Melnova, L., et al. (1995) Diagnosis of Pleural Effusions: Experience with Clinical Studies, 1986 to 1990. Chest, 107, 1598-1603.
https://doi.org/10.1378/chest.107.6.1598
[2]
Heffner, J.E., Brown, L.K. and Barbieri, C.A. (1997) Diagnostic Value of Tests That Discriminate between Exudative and Transudative Pleural Effusions. Primary Study Investigators. Chest, 111, 970-980. https://doi.org/10.1378/chest.111.4.970
[3]
Burrows, C.M., Mathews, W.C. and Colt, H.G. (2000) Predicting Survival in Patients with Recurrent Symptomatic Malignant Pleural Effusions: An Assessment of the Prognostic Values of Physiologic, Morphologic, and Quality of Life Measures of Extent of Disease. Chest, 117, 73-78. https://doi.org/10.1378/chest.117.1.73
[4]
Morgensztern, D., Waqar, S., Subramanian, J., et al. (2012 ) Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 7, 1485-1489.
[5]
Rakha, E.A., Patil, S., Abdulla, K., et al. (2010) The Sensitivity of Cytologic Evaluation of Pleural Fluid in the Diagnosis of Malignant Mesothelioma. Diagnostic Cytopathology, 38, 874-879. https://doi.org/10.1002/dc.21303
[6]
Brock, M.V., Hooker, C.M., Yung, R., et al. (2005) Can We Improve the Cytologic Examination of Malignant Pleural Effusions Using Molecular Analysis? Annals of Thoracic Surgery, 80, 1241-1247.
[7]
Puzman, P., Terl, M. and Mukensnabl, P. (2006) Medical Video-Thoracoscopy in Diagnosis and Therapy of Pleural Effusions. Vnitrní Lékarství, 52, 321-327.
[8]
Thomas, J.M. and Musani, A.I. (2013) Malignant Pleural Effusions: A Review. Clinics in Chest Medicine, 34, 459-471. https://doi.org/10.1016/j.ccm.2013.05.004
[9]
Gu, Q., Hu, C. and Qu, J. (2013) Good Response of Malignant Pleural Effusion from Carcinoma of Unknown Primary Site to the Anti-Tuberculosis Therapy: A Case Report. International Journal of Clinical & Experimental Pathology, 6, 973-977.
[10]
Shin, S., Sung, B., Cho, Y., et al. (2001) An Anti-Apoptotic Protein Human Survivin Is a Direct Inhibitor of Caspase-3 and 7. Biochemistry, 40, 1117-1123.
https://doi.org/10.1021/bi001603q
[11]
Shinohara, E.T., Gonzalez, A., Massion, P.P., et al. (2005) Nuclear Surviving Predicts Recurrence and Poor Survival in Patients with Resected Non-Small Cell Lung Carcinoma. Cancer, 103, 1685-1692. https://doi.org/10.1002/cncr.20951
[12]
Shintani, M., Sangawa, A., Yamao, N., et al. (2013) Immunohistochemical Expression of Nuclear and Cytoplasmic Survivin in Gastrointestinal Carcinoma. International Journal of Clinical & Experimental Pathology, 6, 2919-2927.
[13]
Warnecke-Eberz, U., Baldus, S.E., Bollschweiler, E., et al. (2008) Up-Regulation of Survivin mRNA Might Be a Marker for Non-Invasive Detection of Non-Small Cell Lung Cancer Rather Than for Prognosis. Anticancer Research, 28, 1525-1529.
[14]
Li, F., Ambrosini, G., Chu, E.Y., et al. (1998) Control of Apoptosis and Mitotic Spindle Checkpoint by Surviving. Nature, 396, 580-584.
https://doi.org/10.1038/25141
[15]
Yamamoto, T. and Tanigawa, N. (2001) The Role of Survivin as a New Target of Diagnosis and Treatment in Human Cancer. Medical Electron Microscopy, 34, 207-212. https://doi.org/10.1007/s007950100017
[16]
Church, D.N. and Talbot, D.C. (2012) Survivin in Solid Tumors: Rationale for Development of Inhibitors. Current Oncology Reports, 14, 120-128.
https://doi.org/10.1007/s11912-012-0215-2
[17]
Nachmias, B., Ashhab, Y. and Ben-Yehuda, D. (2004) The Inhibitor of Apoptosis Protein Family (IAPs): An Emerging Therapeutic Target in Cancer. Seminars in Cancer Biology, 14, 231-243. https://doi.org/10.1016/j.semcancer.2004.04.002
[18]
Altieri, D.C. (2003) Validating Survivin as a Cancer Therapeutic Target. Nature Reviews Cancer, 3, 46-54. https://doi.org/10.1038/nrc968
[19]
Naumnik, W., Nilklinska, W., Ossolinska, M., et al. (2009) Serum Levels of HMGB1, Survivin, and VEGF in Patients with Advanced Non-Small Cell Lung Cancer during Chemotherapy. Folia Histochemica et Cytobiologica, 47, 703-709.
https://doi.org/10.2478/v10042-009-0024-0
[20]
Derin, D., Soydinc, H.O., Guney, N., et al. (2008) Serum Levels of Apoptosis Biomarkers, Survivin and TNF-Alpha in Non-Small Cell Lung Cancer. Lung Cancer, 59, 240-245. https://doi.org/10.1016/j.lungcan.2007.08.005
[21]
Tian, P., Shen, Y., Wan, C., et al. (2014) Diagnostic Value of Survivin for Malignant Pleuraleffusion: A Clinical Study and Meta-Analysis. Postgraduate Medicine, 7, 5880-5887.
[22]
Li, J., Li, Z.N., Bao, Q.L., Ge, L.P., et al. (2012) Evaluation of Pleural Fluid Survivin and XIAP for the Diagnosis of Malignant Pleural Effusion. Tumor Biology, 33, 1803-1810. https://doi.org/10.1007/s13277-012-0439-7
[23]
Lan, C.-C., Wu, Y.-K., Lee, C.-H., et al. (2010) Increased Survivin mRNA in Malignant Pleural Effusion Is Significantly Correlated with Survival. Japanese Journal of Clinic Oncology, 40, 234-240. https://doi.org/10.1093/jjco/hyp151
[24]
Aitaliev, Sh.M., Alekseeva, L.A. and Zhanbyrbaev, N.B. (2012) The Utility of Survivin mRNA as a Diagnostic Biomarker in Lung Cancer with Malignant Pleural Effusion. Egyptian Journal of Chest Diseases and Tuberculosis, 61, 103-108.
https://doi.org/10.1016/j.ejcdt.2012.10.029
[25]
Wu, Y.K., Chen, K.T., Kuo, Y.B., et al. (2009) Quantitative Detection of Survivin in Malignant Pleural Effusion for the Diagnosis and Prognosis of Lung Cancer. Cancer Letters, 273, 331-335. https://doi.org/10.1016/j.canlet.2008.08.023
[26]
Park, D.S., Hwang, K.E., Shim, H., et al. (2012) Elevated Survivin Is Associated with a Poor Response to Chemotherapy and Reduced Survival in Lung Cancer with Malignant Pleural Effusions. Clinical & Experimental Metastasis, 29, 83-89.
https://doi.org/10.1007/s10585-011-9431-7
